ABBV Inks Drug Pricing Deal With Trump, Joins PD-1xVEGF Bandwagon

Key Takeaways ABBV agreed to lower U.S. drug prices to match comparable developed markets under MFN terms.Under the pact, ABBV commits $100B over the next decade to boost U.S. R&D and manufacturing capacity.ABBV licensed RemeGen's PD-1xVEGF bispecific RC148 for up to $5.6B to expand its solid tumor pipeline.AbbVie (ABBV) announced that it has signed an agreement with the Trump administration to lower drug prices in the United States.Under the agreement, AbbVie has agreed to reduce the prices of its prescrip ...